Zepbound
Tirzepatide, FDA-approved for weight loss.
Zepbound is Eli Lilly's FDA-approved tirzepatide specifically indicated for chronic weight management in adults with obesity or overweight with weight-related conditions. The same compound as Mounjaro, optimized at the highest approved doses for the most significant weight loss outcomes available in prescription medicine today.
Key Benefits
- ✓FDA-approved specifically for weight loss
- ✓Average weight loss of 20–22% at highest dose
- ✓Largest weight loss results of any approved medication
- ✓Once-weekly injection for consistent results
- ✓Improves metabolic and cardiovascular health
- ✓Provider-supervised for safety and efficacy
Quick Facts
Zepbound contains tirzepatide — a novel dual GIP and GLP-1 receptor agonist. By simultaneously activating both hormone pathways, it produces a more complete metabolic response: stronger appetite suppression, enhanced insulin response, reduced glucagon, and direct effects on adipose tissue metabolism. In the SURMOUNT-1 trial, participants taking the 15mg dose lost an average of 22.5% of their body weight — the highest ever recorded for a pharmacological weight loss therapy.
More from Weight Loss
You Might Also Like
All prescription treatments require approval from a licensed healthcare provider. Results may vary. This product has not been evaluated by the FDA for the specific indications described. Reclaimed is a telehealth platform — we facilitate connections between patients and licensed providers, not the practice of medicine directly. Please consult your provider with any questions about your treatment.